Nov 12 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt
GDRB.BU CEO Gabor Orban:
* 2024 GUIDANCE REITERATED
* PHARMA REVENUES AND CLEAN EBIT EXPECTED TO COME IN CLOSER
TO THE
LOWER END OF THE UNCHANGED GUIDANCE RANGE
* EXCHANGE RANGE MOVEMENTS PROVIDED TAILWIND
* WE SAW DOUBLE-DIGIT GROWTH IN ALL SEGMENTS IN Q3
* OPERATING EXPENSES WERE HIGHER THAN EXPECTED DUE TO
ACQUISITIONS
* LOWER VRYLAR INCOME WAS OFFSET BY MILESTONE PAYMENT FROM
ABBVIE
AFTER NEW RESEARCH AND DEVELOPMENT COLLABORATION SIGNED IN
OCTOBER
Source text: [https://bet.hu/newkibdata/129151822/PresentationQ32024.pdf
]
Further company coverage: GDRB.BU
(Reporting by Anita Komuves)
((KOMUVES.Anita@thomsonreuters.com;))